We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Polyspecific Antibodies for Cancer Research


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Polyspecific Antibodies for Cancer Research"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

AMSBIO announce a new range of high-quality bispecific antibodies (BsAbs) and trispecific antibodies (TsAbs) that can used to provide enhanced cancer therapeutic efficacy and/or safety compared to what can be achieved with conventional monospecific antibodies.


The concept of using a molecule with more than one binding site to enhance its biological function has been around for some time. Polyspecific antibodies are the basis of a new class of anti-cancer agents which offer the potential to be directed at multiple tumor antigens to eradicate tumor cells more precisely and effectively.


Polyspecific monoclonal antibodies are genetically engineered proteins that can simultaneously engage two or more different types of epitopes. There are many building block formats to generate BsAbs and TsAbs based on combining the antigen recognition domains of monoclonal antibodies (mAbs).


Bispecific antibodies and trispecific antibodies offer a range of advantages over monoclonal antibodies. This includes that they can redirect specific polyclonal immune cells such as T cells and NK cells to tumor cells to enhance tumor killing, or simultaneously block two different pathways with unique or overlapping functions in pathogenesis. Additionally, BsAbs and TsAbs potentially increase binding specificity by interacting with multiple different cell surface antigens instead of one, as well as reducing development and production costs when compared to multiple single based antibodies used in combination therapy or compared to the production of CAR-T cells.


Pre-clinical studies and early phase clinical trials have demonstrated that bispecific and trispecific antibody therapy offer improved treatment of solid tumor malignancies and highlights the potential they hold for future therapies to come.

  

Advertisement